Percentage of Subjects Who Serologically Convert to Each of Human Papilloma Virus (HPV) 6, 11, 16, 18 at Week 4 Postdose 3 (Month 7) 7 months [clinicaltrials_resource:7e46f4ea72a14e4d753bd770d449ee26]
Month 7 HPV cLIA seroconversion rates among subjects who received Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) L 1 VLP vaccine (per‐protocol immunogenicity population ).
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Percentage of Subjects Who Serologically Convert to Each of Human Papilloma Virus (HPV) 6, 11, 16, 18 at Week 4 Postdose 3 (Month 7) 7 months [clinicaltrials_resource:7e46f4ea72a14e4d753bd770d449ee26]
Month 7 HPV cLIA seroconversion rates among subjects who received Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) L 1 VLP vaccine (per‐protocol immunogenicity population ).
Bio2RDF identifier
7e46f4ea72a14e4d753bd770d449ee26
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:7e46f4ea72a14e4d753bd770d449ee26
measure [clinicaltrials_vocabulary:measure]
Percentage of Subjects Who Ser ...... at Week 4 Postdose 3 (Month 7)
time frame [clinicaltrials_vocabulary:time-frame]
description
Month 7 HPV cLIA seroconversio ...... l immunogenicity population ).
identifier
clinicaltrials_resource:7e46f4ea72a14e4d753bd770d449ee26
title
Percentage of Subjects Who Ser ...... Postdose 3 (Month 7) 7 months
@en
type
label
Percentage of Subjects Who Ser ...... 6f4ea72a14e4d753bd770d449ee26]
@en